癌症研究
伊马替尼
酪氨酸激酶
酪氨酸激酶抑制剂
达沙替尼
生长因子受体
血小板源性生长因子受体
癌症
受体酪氨酸激酶
髓系白血病
CD135型
甲磺酸伊马替尼
靶向治疗
生物
阿布勒
ROR1型
主旨
癌细胞
信号转导
激酶
间质细胞
细胞因子
原癌基因酪氨酸蛋白激酶Src
白血病
癌基因
医学
生长因子
酪氨酸磷酸化
免疫学
细胞生长
免疫疗法
作者
Dilpreet Singh,S. Dhankhar,Karan Goel,Samrat Chauhan,Sumesh Chandra Sharma,Monika Saini,Thakur Gurjeet Singh,Somdutt Mujwar
标识
DOI:10.2174/0113816128488564260713055506
摘要
Imatinib, a Tyrosine Kinase Inhibitor (TKI) that targets the first-in-class, has been a major factor in the change of cancer treatment aimed at precision by selectively blocking Breakpoint Cluster Region-Abelson murine leukemia viral oncogene (BCR-ABL), KIT proto-oncogene receptor tyrosine kinase (c-KIT), and platelet-Derived Growth Factor Receptors (PDGFRs), along with additional inhibitory activity against Src Family Kinases (SFKs). Apart from Chronic Myeloid Leukemia (CML), for which it was first approved, clinicians have now expanded its application to include Gastrointestinal Stromal Tumors (GIST), Dermatofibrosarcoma Protuberans (DFSP), and kinase-driven cancers of various types. Imatinib inhibits phosphorylation and activation of cancer pathways by competitively binding to the ATP-binding site on these kinases. Inhibiting BCR-ABL thus deprives the leukemic cells of growth and survival signals. In the same way, inhibition of c-KIT and PDGFR results in GIST and DFSP tumor growth retardation through the impact on signaling pathways like PI3K/AKT (cell survival and proliferation), RAS/MAPK (tumor growth and differentiation), and JAK/STAT (immune evasion and cytokine signaling). Moreover, imatinib exerts anti-angiogenic properties by lowering the production of pro-angiogenic factors, hence preventing tumor vascularization. However, the drawback of imatinib in the form of resistance issues still hampers the progress of the dominant division. The causes of this phenomenon are secondary mutations, alterations of the kinase domain, activation of alternative pathways, and clonal evolution. This explores imatinib's inner mechanism in detail, the pivotal role it plays in modulating tumor/stromal cell interactions, as well as the impact that resistance mechanisms have on the therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI